136 related articles for article (PubMed ID: 11700044)
1. Site-directed mutagenesis identifies active-site residues of the light chain of botulinum neurotoxin type A.
Rigoni M; Caccin P; Johnson EA; Montecucco C; Rossetto O
Biochem Biophys Res Commun; 2001 Nov; 288(5):1231-7. PubMed ID: 11700044
[TBL] [Abstract][Full Text] [Related]
2. Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization.
Binz T; Bade S; Rummel A; Kollewe A; Alves J
Biochemistry; 2002 Feb; 41(6):1717-23. PubMed ID: 11827515
[TBL] [Abstract][Full Text] [Related]
3. Active-site mutagenesis of tetanus neurotoxin implicates TYR-375 and GLU-271 in metalloproteolytic activity.
Rossetto O; Caccin P; Rigoni M; Tonello F; Bortoletto N; Stevens RC; Montecucco C
Toxicon; 2001 Aug; 39(8):1151-9. PubMed ID: 11306125
[TBL] [Abstract][Full Text] [Related]
4. Role of two active site Glu residues in the molecular action of botulinum neurotoxin endopeptidase.
Kukreja RV; Sharma S; Cai S; Singh BR
Biochim Biophys Acta; 2007 Feb; 1774(2):213-22. PubMed ID: 17189717
[TBL] [Abstract][Full Text] [Related]
5. Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.
Ahmed SA; Olson MA; Ludivico ML; Gilsdorf J; Smith LA
Protein J; 2008 Apr; 27(3):151-62. PubMed ID: 18213512
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.
Dolly JO; Wang J; Zurawski TH; Meng J
FEBS J; 2011 Dec; 278(23):4454-66. PubMed ID: 21645262
[TBL] [Abstract][Full Text] [Related]
7. Common binding site for disialyllactose and tri-peptide in C-fragment of tetanus neurotoxin.
Jayaraman S; Eswaramoorthy S; Kumaran D; Swaminathan S
Proteins; 2005 Nov; 61(2):288-95. PubMed ID: 16104015
[TBL] [Abstract][Full Text] [Related]
8. Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis.
Washbourne P; Pellizzari R; Baldini G; Wilson MC; Montecucco C
FEBS Lett; 1997 Nov; 418(1-2):1-5. PubMed ID: 9414082
[TBL] [Abstract][Full Text] [Related]
9. Unique substrate recognition by botulinum neurotoxins serotypes A and E.
Chen S; Barbieri JT
J Biol Chem; 2006 Apr; 281(16):10906-11. PubMed ID: 16478727
[TBL] [Abstract][Full Text] [Related]
10. Structural analysis of the catalytic domain of tetanus neurotoxin.
Rao KN; Kumaran D; Binz T; Swaminathan S
Toxicon; 2005 Jun; 45(7):929-39. PubMed ID: 15904688
[TBL] [Abstract][Full Text] [Related]
11. Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain.
Li L; Binz T; Niemann H; Singh BR
Biochemistry; 2000 Mar; 39(9):2399-405. PubMed ID: 10694409
[TBL] [Abstract][Full Text] [Related]
12. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
[TBL] [Abstract][Full Text] [Related]
13. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW; Chai Q; Christian T; Stevens RC
Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of action of botulinum toxins and neurotoxins].
Poulain B; Lonchamp E; Jover E; Popoff MR; Molgó J
Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S73-6. PubMed ID: 19576489
[TBL] [Abstract][Full Text] [Related]
15. Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
Lam KH; Sikorra S; Weisemann J; Maatsch H; Perry K; Rummel A; Binz T; Jin R
Pathog Dis; 2018 Jun; 76(4):. PubMed ID: 29688327
[TBL] [Abstract][Full Text] [Related]
16. Location of the synaptosome-binding regions on botulinum neurotoxin B.
Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ
Biochemistry; 2012 Jan; 51(1):316-28. PubMed ID: 22146011
[TBL] [Abstract][Full Text] [Related]
17. Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin.
Chen S; Hall C; Barbieri JT
J Biol Chem; 2008 Jul; 283(30):21153-9. PubMed ID: 18511417
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type B (Myobloc): pharmacology and biochemistry.
Callaway JE
Clin Dermatol; 2004; 22(1):23-8. PubMed ID: 15158541
[TBL] [Abstract][Full Text] [Related]
19. High Conservation of Tetanus and Botulinum Neurotoxins Cleavage Sites on Human SNARE Proteins Suggests That These Pathogens Exerted Little or No Evolutionary Pressure on Humans.
Carle S; Pirazzini M; Rossetto O; Barth H; Montecucco C
Toxins (Basel); 2017 Dec; 9(12):. PubMed ID: 29257047
[TBL] [Abstract][Full Text] [Related]
20. Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E.
Kukreja RV; Singh BR
Biochemistry; 2007 Dec; 46(49):14316-24. PubMed ID: 18004882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
